Breast Cancer Risk Assessment: A Guide for Clinicians Using the NCCN Breast Cancer Risk Reduction Guidelines

Authors:
Sofia D. MerajverFrom Breast and Ovarian Cancer Risk Evaluation Clinic, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.

Search for other papers by Sofia D. Merajver in
Current site
Google Scholar
PubMed
Close
 MD, PhD
and
Kara MillironFrom Breast and Ovarian Cancer Risk Evaluation Clinic, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.

Search for other papers by Kara Milliron in
Current site
Google Scholar
PubMed
Close
 MS, CGC
View More View Less
Full access

Breast cancer, a complex and heterogeneous disease, is the most common malignancy diagnosed in women in the United States, with over 180,000 new cases and approximately 44,000 deaths per year. Breast cancer risk is influenced by a large number of factors, including age, family history, reproductive and hormonal history, proliferative breast conditions, physical activity, diet, and environmental exposures. These factors all interact in a complex manner to contribute to the risk of developing breast cancer. Because the interactions between risk factors are poorly understood at the molecular level, it is difficult to accurately evaluate the breast cancer risk of a given person presenting with an individual constellation of factors. To better define the population at increased risk that may warrant specific intervention, several models exist to estimate a woman's risk for developing breast cancer and for harboring a germline mutation in a cancer susceptibility gene. This article summarizes these models and gives brief guidelines about which model may be preferable given a specific family history.

Correspondence: Sofia D. Merajver, M.D., Ph.D., Breast and Ovarian Cancer Risk Evaluation Clinic, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan. E-mail: smerajve@umich.edu.
  • Collapse
  • Expand
  • 1

    Ries LAG, Kosary CL, Hankey BF et al.. SEER Cancer Statistics Review, 1993–1996. Bethesda: National Institutes of Health, 1999.

  • 2

    Stewart AK, Bland KI, McGinnis LS Jr et al.. Clinical highlights from the National Cancer Data Base, 2000. CA Cancer J Clin 2000;50:171183.

  • 3

    Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146151.

  • 4

    Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993;270:15631568.

    • Search Google Scholar
    • Export Citation
  • 5

    Colditz GA, Willett WC, Hunter DJ et al.. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA 1993;270:338343.

    • Search Google Scholar
    • Export Citation
  • 6

    Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131:961972.

  • 7

    Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232242.

  • 8

    Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993;28: 115120.

    • Search Google Scholar
    • Export Citation
  • 9

    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early onset breast cancer. Cancer 1994;73:643651.

  • 10

    Claus EB, Schildkraut JM, Thompson WD et al.. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:23182324.

  • 11

    Peters JA. Applications of genetic technologies to cancer screening, prevention, diagnosis, prognosis, and treatment. Semin Oncol Nurs 1997;13:7481.

    • Search Google Scholar
    • Export Citation
  • 12

    Gail MH, Brinton LA, Byar DP et al.. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:18791886.

    • Search Google Scholar
    • Export Citation
  • 13

    Fisher B, Costantino JP, Wickerham DL et al.. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:13711388.

    • Search Google Scholar
    • Export Citation
  • 14

    Rockhill B, Spiegelman D, Byrne C et al.. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93:358366.

    • Search Google Scholar
    • Export Citation
  • 15

    Gail M, Rimer B. Risk of risk-based mammography screening, age 40 to 49. J Clin Oncol 1999;17:735737.

  • 16

    Couch FJ, DeShano ML, Blackwood MA et al.. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:14091415.

    • Search Google Scholar
    • Export Citation
  • 17

    Frank TS. Testing of hereditary risk of ovarian cancer. Cancer Control 1999;6:327334.

  • 18

    Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145158.

    • Search Google Scholar
    • Export Citation
  • 19

    Berry DA, Iversen ES Jr, Gudbjartsson DF et al.. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20: 27012712.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 89 89 7
PDF Downloads 35 35 9
EPUB Downloads 0 0 0